Esketamine Nasal Spray Shows Rapid Antidepressant Effects As Stand-Alone Treatment For Resistant Depression 

Used as a stand-alone treatment for treatment-resistant depression (TRD), Esketamine nasal spray improved depressive symptoms within 24 hours, and results were maintained for 28 days, according to a recent study. Esketamine nasal spray as a stand-alone treatment for TRD may offer options to people who are unable to tolerate oral antidepressants or who do not respond to oral antidepressants, the researchers concluded.

The phase 4, double-blind, placebo-controlled randomized clinical trial was conducted from November 2020 to January 2024 at 51outpatient centers in the U.S. with 378 adults diagnosed with major depressive disorder (DSM-5 . . .